Please use this identifier to cite or link to this item: https://hdl.handle.net/1822/79335

TitleErythrocyte-derived liposomes for the treatment of inflammatory diseases
Author(s)Olival, Ana Sofia Martins
Vieira, Sara Filipa Fontoura
Gonçalves, V. M. F.
Cunha, C.
Tiritan, M. E.
Carvalho, A.
Reis, R. L.
Ferreira, Helena Susana Costa Machado
Neves, N. M.
KeywordsActive targeting
Anti-inflammatory activity
Drug delivery
Erythrocytes
Inflammatory diseases
Liposomes
Issue dateApr-2022
PublisherTaylor & Francis
JournalJournal of Drug Targeting
CitationOlival A., Vieira S. F., Gonçalves V. M. F., Cunha C., Tiritan M. E., Carvalho A., Reis R. L., Ferreira H., Neves N. M. Erythrocyte-derived liposomes for the treatment of inflammatory diseases, Journal of Drug Targeting, doi:10.1080/1061186X.2022.2066107, 2022
Abstract(s)Effective and safe therapies to counteract persistent inflammation are necessary. We developed erythrocyte-derived liposomes (EDLs) with intrinsic anti-inflammatory activity. The EDLs were prepared using lipids extracted from erythrocyte membranes, which are rich in omega-3 fatty acids with several health benefits. Diclofenac, a widely used anti-inflammatory drug, was incorporated into EDLs in relevant therapeutic concentrations. The EDLs were also functionalised with folic acid to allow their active targeting of M1 macrophages, which are key players in inflammatory processes. In the presence of lipopolysaccharide (LPS)-stimulated macrophages, empty EDLs and EDLs incorporating diclofenac were able to reduce the levels of important pro-inflammatory cytokines, namely interleukin-6 (IL-6; ~85% and 77%, respectively) and tumour necrosis factor-alpha (TNF-a; ~64% and 72%, respectively). Strikingly, cytocompatible concentrations of EDLs presented similar effects to dexamethasone, a potent anti-inflammatory drug, in reducing IL-6 and TNF-a concentrations, demonstrating the EDLs potential to be used as bioactive carriers in the treatment of inflammatory diseases.
TypeArticle
URIhttps://hdl.handle.net/1822/79335
DOI10.1080/1061186X.2022.2066107
ISSN1029-2330
Publisher version10.1080/1061186X.2022.2066107
Peer-Reviewedyes
AccessEmbargoed access (1 Year)
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
20830-erythrocyte-derived-liposomes-treatment.pdf
  Until 2023-05-01
3,6 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID